Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07111182 · ClinicalTrials.gov registry record · NA
Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery
A NA study of Brain Neoplasms, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT07111182 is a NA study of Brain Neoplasms that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 8 participants, below the 256-participant average among 14 other Brain Neoplasms trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07111182, a NA study of Brain Neoplasms, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffuse cell growth and the proximity of functionally critical tissues. The current golden standard for intraoperative glioma detection is fluorescence-guided surgery (FGS) using 5-ALA. In 5-ALA FGS the drug-induced fluorescence helps to visually detect tumor cells, which improves resection rates and delays tumor progression. Tumor cells are often left unnoticed because of visual obstacles or weak fluorescence, which may lead to local recurrence and reoperations. Surgical suction devices are routinely used to remove cancerous tissues, but so far, the analysis of the suction waste has not been used in near real-time tissue detection.
Conditions Studied
Interventions
- DEVICE HIVEN Medical Device
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2027-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07111182
The ClinicalTrials.gov registry entry for NCT07111182 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 256-participant average among 14 other Brain Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which HIVEN Medical Device is the first listed.
NCT07111182 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT07111182 about?
NCT07111182 is a clinical study titled "Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery". Gliomas are tumors that occur in all ages; they include the most common malign primary central nervous system tumors in developed countries. Gliomas are often aggressive, and their recommended treatment is surgical resection and chemoradiation. Complete tumor removal is challenging because of diffus...
What is the current status of trial NCT07111182?
This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2025-10-27. Estimated completion is 2027-12-30.
What conditions does trial NCT07111182 study?
This clinical trial studies the following conditions: Brain Neoplasms.
What interventions are being tested in trial NCT07111182?
The interventions under investigation include: HIVEN Medical Device (DEVICE).
Who is sponsoring clinical trial NCT07111182?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07111182 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Guided Meditation During Radiation Therapy for Brain Tumors
RECRUITING · NA
-
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
RECRUITING · NA
-
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
RECRUITING · NA
-
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.